Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(50.0%)
Phase 4
2(33.3%)
Phase 3
1(16.7%)
6Total
N/A(3)
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03900260Not ApplicableCompleted

Clinical Evaluation of the Lenstec Softec HP1 Intraocular Lens

Role: lead

NCT02487160Phase 3Completed

Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens

Role: lead

NCT00969371Not ApplicableCompleted

Lenstec Tetraflex Accommodating Posterior Chamber Intraocular Lens (IOL) Clinical Investigation

Role: lead

NCT01249144Phase 4Terminated

Visual and Refractive Outcomes After Implantation of Aspheric IOLs With Different Dioptric Increments and Manufacturing

Role: lead

NCT00963742Not ApplicableCompleted

Lenstec Softec HD Posterior Chamber Intraocular Lens Clinical Investigational Protocol

Role: lead

NCT01248572Phase 4Completed

Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL

Role: lead

All 6 trials loaded